Induction of ovulation, lupus and antiphospholipides;Induction d'ovulation, lupus et antiphospholipides

Revue de Medecine Interne

Volumn 22, Issue 2, 2001, Pages 111-117

  Le Thi Huong, D ^a   Wechsler, B ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

In vitro fecondation with embryotransfert; Ovulation induction; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AUTOANTIBODY; CLOMIFENE; CYCLOPHOSPHAMIDE; FOLLITROPIN; GONADORELIN; HEPARIN; HUMAN MENOPAUSAL GONADOTROPIN; INTERLEUKIN 3; PHOSPHOLIPID ANTIBODY; TAMOXIFEN;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL ARTICLE; DISEASE COURSE; EDITORIAL; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GLOMERULONEPHRITIS; HUMAN; INFERTILITY; INFERTILITY THERAPY; OVULATION INDUCTION; PRACTICE GUIDELINE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0035128234     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)00299-X     Document Type: Editorial

References (45)

1. Evaluation and management of infertility in women: The internists'role
2. Pregnancies and births resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990
3. Assisted reproductive technology in the United States and Canada: 1995 Results generated from the American Society Reproductive Medicine/Society for Assisted Reproductive Technology Registry
4. Danish National IVF Registry 1994 and 1995. Treatment, pregnancy outcome and complications during pregnancy
5. Balance générale de FIVNAT 1997
6. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
7. Hormone stimulation and replacement therapy in women with rheumatic disease. Can we advise ovulation induction in patients with SLE?
8. Relation entre pathologie auto-immune multiple et induction d'ovulation
9. Risk of ovulation-induction therapy in systemic lupus erythematosus
10. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation
11. Outcome of planned pregnancies in systemic lupus erythematosus: A prospective study of 62 pregnancies
12. Ovulation-induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome
13. Antiphospholipid antibodies and the outcome of pregnancy after the first in-vitro fertilization and embryo transfer cycle
14. Laboratory evaluation of women experiencing reproductive failure
15. Experimental thrombosis and antiphospholipid antibodies: New insights
16. Antiphospholipid antibodies and the protein C pathway
17. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: A thrombogenic mechanism for the antiphospholipid syndrome
18. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered β2-glycoprotein I
19. High fecundity rate following in vitro fertilization and embryo transfer in antiphospholipid antibody seroposirive women treated with heparin and aspirin
20. Antiphospholipid antibodies in women having in vitro fertilization
21. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
22. Randomised control trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
23. Obstetric management of antiphospholipid syndrome
24. Utilisation thérapeutique des immunoglobulines intraveineuses au cours du syndrome des antiphospholipides
25. Effect of antiphospholipid antibodies in women undergoing in vitro fertilization: Role of heparin and aspirin
26. Antiphospholipid antibodies and infertility: Tact or fallacy
27. Antiphospholipid antibodies and in vitro fertilization success: A meta-analysis
28. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
29. Prednisolone plus low dose aspirin improves the implantation rate in women with autoimmune conditions who are undergoing in vitro fertilization
30. Management of patients with antiphospholipid antibodies undergoing in vitro fertilization
31. The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas
32. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques
33. Influence de la grossesse, de la ménopause et du traitement hormonal substitutif sur l'évolution du lupus érythémateux disséminé
34. Approach to the study of the role of sex hormones in autoimmunity
35. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus
36. Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus
37. Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate
38. Administration of gonadotropin-releasing hormone analog as adjunctive therapy in women with systemic lupus erythematosus
39. Thrombosis with low estrogen oral contraceptives
40. Risk factors for pregnancy venous thromboembolism
41. Ovulation induction with clomiphene citrate complicated by deep vein thromboses
42. The special case of venous thromboembolism in pregnancy
43. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus eythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance
44. Systemic lupus erythematosus and reproductive function: A case-control study
45. Pregnancy complications in women with recurrent miscarriage associated with antiphopsholipid antibodies treated with low dose aspirin and heparin